Published in Health Business Week, January 12th, 2007
Dr. Miriam Kidron, Oramed's chief technology officer, was asked to comment on the comparison of Oramed's insulin capsule versus an insulin inhaler. Dr. Kidron responded, "There is no comparison. The inhaler was designed in an effort to mimic the effects of subcutaneous insulin, which is not physiologically natural. Insulin should not be delivered directly into the bloodstream. Oramed's capsule provides a better physiological entry for insulin."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.